FibroBiologics (NASDAQ: FBLG) completes 1:20 reverse stock split
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
FibroBiologics, Inc. approved a capital change by implementing a one-for-twenty reverse stock split of its common stock. The Certificate of Amendment became effective at 12:01 a.m. Eastern Time on March 30, 2026, converting every 20 issued and outstanding common shares into 1 share.
No fractional shares will be issued; any fractional share will be rounded up to the nearest whole share. The reverse split proportionately adjusts shares available under the equity incentive plan and existing options and warrants, but does not change the common stock’s par value, authorized share count, or the Nasdaq trading symbol FBLG.
Positive
- None.
Negative
- None.
Insights
FibroBiologics’ 1:20 reverse split mainly restructures share count, not fundamentals.
FibroBiologics is consolidating every 20 common shares into 1, effective March 30, 2026. This type of reverse stock split changes the share price and share count relationship but does not directly alter the company’s total equity value.
The move also adjusts equity incentive plan shares and existing options and warrants on a proportional basis, preserving relative ownership and exercise economics. Percentage ownership for most holders remains effectively the same aside from minor rounding from fractional shares, so the change is largely mechanical rather than operational.
8-K Event Classification
3 items: 3.03, 5.03, 9.01
3 items
Item 3.03
Material Modification to Rights of Security Holders
Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Reverse split ratio: 1-for-20
Effective time: 12:01 a.m. Eastern Time
Effective date: March 30, 2026
+2 more
5 metrics
Reverse split ratio
1-for-20
Reverse stock split of issued and outstanding common shares
Effective time
12:01 a.m. Eastern Time
Effective time of reverse stock split on March 30, 2026
Effective date
March 30, 2026
Effective date of reverse stock split
CUSIP number
31573L204
New CUSIP for common stock after reverse split
Par value
$0.00001 per share
Par value of common stock unchanged by reverse split
Key Terms
Reverse Stock Split, Certificate of Amendment, equity incentive plan, par value, +1 more
5 terms
Reverse Stock Split financial
"implemented a one-for-twenty (1:20) reverse stock split (the “Reverse Stock Split”)"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Certificate of Amendment regulatory
"filed a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation"
A certificate of amendment is an official filing that updates a company’s founding documents—its legal “rulebook” that sets share structure, voting rules, name and basic purpose. Think of it like changing the blueprint of a building: small changes are paperwork, big ones can alter who owns how much and who controls decisions. Investors watch these filings because they can affect share counts, voting power, dilution and company value.
equity incentive plan financial
"The Reverse Stock Split will also proportionately adjust the number of shares available under the Company’s equity incentive plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
par value financial
"The Reverse Stock Split did not change the par value of the Common Stock"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What did FibroBiologics (FBLG) change with its reverse stock split?
FibroBiologics implemented a one-for-twenty reverse stock split of its common stock. Every 20 issued and outstanding shares were automatically converted into 1 share, primarily affecting share count and price per share, without changing total equity value or par value.
When did the FibroBiologics 1-for-20 reverse stock split become effective?
The reverse stock split became effective at 12:01 a.m. Eastern Time on March 30, 2026. From that time, all issued and outstanding shares of FibroBiologics common stock reflected the new 1-for-20 consolidated share structure on the company’s records and for trading purposes.
Did the FibroBiologics reverse stock split change ownership percentages?
The reverse stock split is designed to affect all FibroBiologics stockholders uniformly, so percentage ownership generally remains the same. Only minor differences can arise from rounding up fractional shares to whole shares, which may slightly adjust some individual holdings’ precise percentages.
What happened to FibroBiologics’ equity incentive plan, options, and warrants?
The number of shares available under the equity incentive plan and the exercise price and share amounts underlying outstanding options and warrants are proportionately adjusted. This keeps the economic value of these awards consistent with the one-for-twenty reverse stock split’s effects on the common stock.
Did FibroBiologics change its trading symbol or par value after the split?
FibroBiologics kept its Nasdaq trading symbol FBLG and did not change the $0.00001 par value or authorized number of common shares. Only the share count and price relationship changed, along with a new CUSIP number assigned to the post-split common stock.